From Breakthrough to Maturity: How Cell Therapy Is Evolving
Cell therapy has come a long way in just over a decade. What began as...
Why Vaccines Still Matter: Valneva CEO Thomas Lingelbach on Science, Politics, and the Future of Vaccine Innovation
Few areas of healthcare have saved more lives, or generated more debate, than vaccines. For...
From Make-or-Break to Record-Breaking: How One Phase 3 Readout Delivered the Biggest Biotech Stock Surge in NASDAQ History
In biotech, Phase 3 data can change everything, or end everything. Few stories capture that...
Free Database of the Top 100 Public Biotechs in Europe
The FlotBio Map is live at map.flot.bio 🙌 Here’s a bit of background FlotBio Map...
Why AI in Biopharma Didn’t Live Up to the Hype
AI has reshaped entire industries, from software development to entertainment, yet its impact in healthcare...
Why ADCs and Radiopharmaceuticals Are Big Pharma’s New Obsession
Antibody-drug conjugates (ADCs) and radiopharmaceuticals have moved from the fringes of biotech buzzwords into the...
Baker Brothers Investing Secrets: Lessons from One of Biotech’s Most Successful and Private Backers
In a biotech landscape dominated by hype and volatility, the Baker Brothers have emerged as...
The 25 Most Valuable Biotech Companies in Europe in 2025
The biotech industry in Europe is booming, with companies making groundbreaking medical advances, from oncology...
Never Miss a New Episode 💌
Trusted by 2500+ biopharma professionals from top companies like argenx, Roche, and Forbion. No spam, no noise.
Watch & Subscribe
